Spark Therapeutics Inc. (ONCE)

113.31
0.04 0.04
NASDAQ : Health Technology
Prev Close 113.27
Open 113.30
Day Low/High 113.15 / 113.40
52 Wk Low/High 34.53 / 114.20
Volume 3.15M
Avg Volume 1.65M
Exchange NASDAQ
Shares Outstanding 37.75M
Market Cap 4.29B
EPS -2.10
P/E Ratio N/A
Div & Yield N.A. (N.A)
These Are the Best Growth Stocks Right Now in Biotech

These Are the Best Growth Stocks Right Now in Biotech

Top names.

Spark Therapeutics Announces Publication In The Lancet Of Pivotal Phase 3 Clinical Trial Data For Investigational Voretigene Neparvovec

Spark Therapeutics Announces Publication In The Lancet Of Pivotal Phase 3 Clinical Trial Data For Investigational Voretigene Neparvovec

Data show that 65 percent of participants demonstrated the maximal improvement in the clinical trial's primary endpoint, bilateral multi-luminance mobility testing (MLMT), at year one

First Week Of August 18th Options Trading For Spark Therapeutics (ONCE)

Investors in Spark Therapeutics Inc saw new options become available this week, for the August 18th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ONCE options chain for the new August 18th contracts and identified one put and one call contract of particular interest.

Spark Therapeutics Completes Rolling Biologics License Application Submission To FDA for Investigational Gene Therapy Voretigene Neparvovec

Voretigene neparvovec has the potential to be the first pharmacologic treatment for an inherited retinal disease (IRD) and the first gene therapy for a genetic disease in the U.S.

We May Be Back to Maximum Overbought by Thursday

Breadth has a small window to improve from the poor and lagging action we saw last week.

Spark Therapeutics Reaches Analyst Target Price

In recent trading, shares of Spark Therapeutics Inc have crossed above the average analyst 12-month target price of $64.73, changing hands for $64.82/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

Spark Therapeutics Announces $15 Million Milestone Payment From Pfizer For Progress In Hemophilia B Gene Therapy Program

Spark Therapeutics Announces $15 Million Milestone Payment From Pfizer For Progress In Hemophilia B Gene Therapy Program

Second milestone achieved under 2014 global license agreement with Pfizer

Blood Work: A Few Biotech Thoughts From Sunny San Diego and the ASH 2016 Meeting

Blood Work: A Few Biotech Thoughts From Sunny San Diego and the ASH 2016 Meeting

I spent the weekend with thousands of blood disease researchers. This is what happened.

Spark's Hemophilia Gene Therapy Remains Effective Despite Immune Reactions

Spark's Hemophilia Gene Therapy Remains Effective Despite Immune Reactions

Spark believes temporary treatment with steroids can arrest the immune response before it causes factor IX levels to fall to a point where bleeding risk becomes a problem.

The Great 'ASH16' Abstract Drop Mostly Causes Drug Stocks to Do Same

The Great 'ASH16' Abstract Drop Mostly Causes Drug Stocks to Do Same

The American Society of Hematology (ASH) annual meeting is one of the most important medical conferences held each year, focusing on new drugs to treat blood-related diseases, including blood cancers.

TheStreet Quant Rating: D+ (Sell)